-
Here's Why Corbus Pharmaceuticals Fell 10% Thursday Morning
Thursday, March 30, 2017 - 9:56am | 390Read More...Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) were trading lower by around 10 percent Thursday morning, even though the company reported positive, top-line data from an ongoing clinical trial. Corbus has been exploring its Anabasum (Resunab) therapy in a Phase 2 study for the...
-
6 Best Biotech Stocks Of 2016
Friday, December 23, 2016 - 12:25pm | 1050Read More...The year 2016 has been a tumultuous one for biotech stocks. The NYSE ARCA BIOTECH INDEX has lost 16.26 percent in the year-to-date period, even as the broader market gauges have rallied to new highs. Biotech ETFs didn't fare any better. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:...
-
JMP Analyst Tries To Clear Up Confusion On Corbus Pharma's Trial Data
Tuesday, November 15, 2016 - 4:16pm | 292Read More...Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) announced Monday top line results from a second stage trial of its Resunab (JBT-101) therapy for the treatment of systemic sclerosis treatment. Liisa Bayko of JMP Securities commented in a report that there appears to be some confusion...
